TABLE 4:

Results of Meta-Regression Analysis of MRI for Detection of Extramural Venous Invasion (EMVI) in Colorectal Cancer

Covariate, Category	No. of Studies	Meta-Analysis Summary Estimates
		Sensitivity (95% CI)	Specificity (95% CI)	p
Location of primary tumor				0.61
Rectum	8	0.56 (0.43–0.70)	0.88 (0.80–0.95)
Any other colon	6	0.67 (0.51–0.83)	0.85 (0.74–0.95)
Neoadjuvant treatment				0.92
No	8	0.61 (0.47–0.75)	0.85 (0.77–0.94)
Yes or mixed	6	0.59 (0.43–0.76)	0.88 (0.79–0.97)
Multi- or single-center study				0.76
Multicenter study	1	0.47 (0.07–0.88)	0.86 (0.63–1.00)
Single-center study	13	0.61 (0.51–0.72)	0.87 (0.80–0.93)
Study design				0.34
Prospective	2	0.53 (0.26–0.81)	0.95 (0.87–1.00)
Retrospective	12	0.62 (0.50–0.73)	0.85 (0.78–0.91)
Definition of reference standard				0.22
Strictly EMVI	7	0.65 (0.52–0.77)	0.89 (0.81–0.97)
Lymphovascular invasion or unclear definition	7	0.54 (0.40–0.69)	0.84 (0.73–0.94)
Frequency of high T category (%)				< 0.01
≥ 67.3	7	0.61 (0.49–0.74)	0.88 (0.80–0.96)
< 67.3	4	0.62 (0.44–0.79)	0.77 (0.62–0.93)
Magnet field strength (T)				0.58
3	5	0.55 (0.38–0.72)	0.90 (0.82–0.98)
< 3	9	0.64 (0.50–0.77)	0.84 (0.75–0.93)
Antispasmodic agents				< 0.01
Used	5	0.58 (0.37–0.79)	0.88 (0.78–0.97)
Not used	2	0.59 (0.30–0.87)	0.91 (0.81–1.00)
High-resolution MRI (voxel size < 0.8 mm)				< 0.01
Yes	8	0.58 (0.44–0.72)	0.89 (0.83–0.0.95)
No	4	0.63 (0.44–0.82)	0.78 (0.64–0.92)
Contrast-enhanced MRI				0.42
Used	2	0.77 (0.54–1.00)	0.86 (0.67–1.00)
Not used	12	0.58 (0.47–0.69)	0.87 (0.80–0.93)
DWI				0.17
Used	3	0.82 (0.63–1.00)	0.84 (0.68–1.00)
Not used	11	0.57 (0.46–0.67)	0.87 (0.81–0.94)
Multiparametric approacha				0.32
Yes	4	0.73 (0.54–0.93)	0.88 (0.77–0.99)
No	10	0.57 (0.46–0.69)	0.86 (0.79–0.94)

^aEither contrast-enhanced MRI or DWI in addition to T2-weighted imaging.